Bionano Genomics (NASDAQ:BNGO) Announces Quarterly Earnings Results, Beats Estimates By $0.78 EPS

Bionano Genomics (NASDAQ:BNGO) announced its quarterly earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.78, FiscalAI reports. Bionano Genomics had a negative return on equity of 86.36% and a negative net margin of 134.36%.The company had revenue of ($20,528.49) million during the quarter, compared to the consensus estimate of $7.88 million.

Here are the key takeaways from Bionano Genomics’ conference call:

• Bionano initiated 2026 revenue guidance of $30 million–$33 million (about 5%–16% growth) and Q1 guidance of $6.5 million–$6.7 million, signaling management expects recovery and growth in 2026.
• The company has shifted to a consumables/software-driven model focused on high-volume “routine use” customers; these routine users (~30–40% of customers) generated about 83% of OGM consumables revenue in 2025 and are the primary target for future growth.
• Profitability improvements are material — full-year non‑GAAP gross margin rose to 47%, non‑GAAP operating expense fell 47% to $36.6 million, the company says it removed ~$100 million of annualized expense, and senior secured convertible debt is expected to be retired in May 2026.
• Revenue and supply headwinds persist — FY2025 revenue declined 7% to $28.5 million (Q4 down 3%), flow‑cell sales were essentially flat, and late‑Q4 wafer manufacturing delays constrained consumable supply; cash on hand was ~$29.6 million with a stated runway into 2027, posing near‑term liquidity risk.
• Adoption and reimbursement catalysts are accumulating — Bionano secured a second Category I CPT code and saw the hematology CPT price rise ~47% to $1,853.22, recorded ~450 publications in 2025, and rolled out software/hardware upgrades (VIA 7.2, Solve 3.8.3, Stratys compute) that increase throughput and broaden application scope.

Bionano Genomics Stock Performance

Shares of BNGO stock opened at $1.46 on Tuesday. The company has a current ratio of 2.12, a quick ratio of 1.82 and a debt-to-equity ratio of 0.07. Bionano Genomics has a 12-month low of $1.06 and a 12-month high of $5.50. The business’s 50 day moving average is $1.25 and its two-hundred day moving average is $1.67. The company has a market capitalization of $14.86 million, a P/E ratio of -0.31 and a beta of 1.69.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price (down from $11.00) on shares of Bionano Genomics in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.50.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BNGO. DRW Securities LLC purchased a new position in Bionano Genomics in the 4th quarter valued at $258,000. Geode Capital Management LLC raised its position in shares of Bionano Genomics by 148.8% in the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after buying an additional 39,928 shares during the last quarter. Carret Asset Management LLC raised its position in shares of Bionano Genomics by 76.4% in the fourth quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after buying an additional 19,100 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Bionano Genomics in the fourth quarter worth about $57,000. Finally, Jane Street Group LLC purchased a new position in shares of Bionano Genomics in the fourth quarter worth about $34,000. 11.35% of the stock is owned by institutional investors and hedge funds.

Bionano Genomics Company Profile

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.